Effects of Cilostazol on Peroxisome Proliferators-Activated Receptor-Γ in Diabetic Rat Kidney

LI Mei,ZHANG Xiu-mei,HU Jian-ting,GAO Ling
DOI: https://doi.org/10.3969/j.issn.1005-1678.2006.04.002
2006-01-01
Abstract:PurposeTo investigate the effect of cilostazol on peroxisome proliferators-activated receptor-γ(PPAR-γ) in diabetic rat kidney.MethodsThe diabetic model was prepared by injecting streptozocin(STZ) intraperitoneally.Male SD rats were divided into 4 groups: normal group,diabetes group,high-dose of cilostazol group[(25 mg/(kg·d)] and low-dose of cilostazol group[(18 mg/(kg·d)].At the end of 12th we-ek,all animals were sacrificed.The following parameters were measured: fasting blood glucose(BG),HbA1c,and the ratio of kidney weight to body weight,the level of PPAR-γ mRNA was semi-quantitated by RT-PCR and the protein expression was detected by western-blot.ResultsThe level of BG not only in low-dose cilostazol group but also in high-dose cilostazol group was not decreased significantly.There was significant increase in the ratio of kidney weight to body weight in diabetes control group compared with normal group(P0.01),and cilostazol could reduce kidney hypertrophy.Cilostazol down-regulated the mRNA and protein levels of PPAR-γ significantly(P0.05).ConclusionCilostazol may play a protective role on kidney by activating PPARγ,and alleviating renal injury in diabetic rats.
What problem does this paper attempt to address?